CLINICAL POLICY: Jardiance (empagliflozin)
EFFECTIVE DATE: 03/01/2025
LAST REVIEW DATE: 02/15/2025

I. INDICATIONS
Jardiance is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.

II. CRITERIA FOR INITIAL APPROVAL
Jardiance may be approved when ALL of the following are met:
1. Diagnosis: Member has a confirmed diagnosis of Type 2 Diabetes Mellitus.
2. Cardiovascular Disease: Member has established cardiovascular disease, as evidenced by one of the following:
   a. History of myocardial infarction
   b. History of coronary artery bypass grafting (CABG)
   c. History of percutaneous coronary intervention (PCI)
   d. History of stroke
3. Age: Member is ≥ 18 years of age.
4. eGFR: Member's estimated glomerular filtration rate (eGFR) is ≥ 45 mL/min/1.73m².

III. DURATION OF APPROVAL
Initial approval: 12 months
Renewal approval: 12 months

IV. RENEWAL CRITERIA
For renewal, the following must be demonstrated:
1. Continued use of Jardiance is producing a positive clinical response.
2. eGFR remains ≥ 45 mL/min/1.73m².
